Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

被引：10
|
作者：
Ettl, Johannes [1 ]
机构：
[1] Tech Univ Munich, Dept Obstet & Gynecol, Klinikum Rechts Isar, Munich, Germany
来源：
BREAST CARE | 2016年 / 11卷 / 03期
关键词：
Advanced breast cancer; Palbociclib; CDK4/6; Endocrine therapy; Cell cycle; DEPENDENT KINASE 4/6; 1ST-LINE TREATMENT; SUBGROUP ANALYSIS; LETROZOLE L; PD; 0332991; PALOMA-1/TRIO-18; COMBINATION; TRIAL; EFFICACY; SAFETY;
D O I：
10.1159/000447417
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed. (C) 2016 S. Karger GmbH, Freiburg
引用
收藏
页码：174 / 176
页数：3
相关论文
共 50 条
  • [1] CDK4/6 inhibitors in HR-positive breast cancer immunotherapy
    Shen, Mimi
    Ma, Zhiyuan
    Zhu, Jiaxing
    Wen, Guorong
    Jin, Hai
    An, Jiaxing
    Tuo, Biguang
    Liu, Xuemei
    Li, Taolang
    BIOORGANIC CHEMISTRY, 2025, 154
  • [2] The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis
    Ding, Wu
    Li, Zhian
    Wang, Caiyun
    Ruan, GuoDong
    Chen, LuPing
    Tu, Chuanjian
    MEDICINE, 2018, 97 (20)
  • [3] Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
    Lu, Janice
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [4] Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
    Janice Lu
    Journal of Hematology & Oncology, 8
  • [5] HR-positive, HER2-negative Breast Cancer Prolongation of Survival by the CDK4 & 6 Inhibitor Abemaciclib
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (12) : 690 - 691
  • [6] Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer
    Chen, Fengquan
    Liu, Chunxi
    Zhang, Jian
    Xu, Wenfang
    Zhang, Yingjie
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 18 (09) : 1241 - 1251
  • [7] PALBOCICLIB: CDK4/6 INHIBITION IN THE TREATMENT OF ER-POSITIVE BREAST CANCER
    Owsley, J.
    Jimeno, A.
    Diamond, J. R.
    DRUGS OF TODAY, 2016, 52 (02) : 119 - 129
  • [8] Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer
    Lenihan, C.
    Bouchekioua-Bouzaghou, K.
    Shia, A.
    Wilkes, E.
    Casado-Izguierdo, P.
    Cutillas, P.
    Schmid, P.
    CANCER RESEARCH, 2016, 76
  • [9] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [10] Pre-clinical analysis of the CDK4/6 inhibitor palbociclib in HER2-positive breast cancer.
    ElChaarani, Bilal
    Stires, Hillary
    Pohlmann, Paula Raffin
    Riggins, Rebecca
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345